Sign up to save your podcasts
Or
Share Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more
Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 4, 2024, issue.
View all episodes
By JAMA Network
3.9
120120 ratings
Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 4, 2024, issue.
More shows like JAMA Editors' Summary
View all
NEJM This Week
314 Listeners
JACC Podcast
160 Listeners
This Week in Cardiology
854 Listeners
JAMA Clinical Reviews
478 Listeners
AFP: American Family Physician Podcast
688 Listeners
Mayo Clinic Talks
283 Listeners
The Curbsiders Internal Medicine Podcast
3,324 Listeners
JAMA Medical News
91 Listeners
Core IM | Internal Medicine Podcast
1,085 Listeners
Annals On Call Podcast
174 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
318 Listeners
Run the List
245 Listeners
Cardionerds: A Cardiology Podcast
413 Listeners
The Curious Clinicians
364 Listeners